Lipocine (LPCN) announced a license, development and supply agreement with to SPC Korea granting exclusive rights to market Tlando in South Korea. Under the terms of the distribution and license agreement, Lipocine will receive an upfront payment and is also eligible to receive certain regulatory and sales milestone payments, including a payment upon regulatory approval of Tlando in South Korea. Lipocine is entitled to royalties on net commercial sales. Lipocine will supply Tlando to SPC Korea and will receive a supply price. SPC Korea will assume responsibility for obtaining regulatory approval within the territory.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter